Windlas Biotech (WINDLAS)
STALWARTFairStock Score: 33/100 — RISKY
Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹894.55 |
| Market Cap | ₹1,591.33 Cr |
| P/E Ratio | 23.84 |
| ROCE | 16.96% |
| ROE | 14.15% |
| Dividend Yield | 0.77% |
| Profit Growth | -3.72% |
| Debt/Equity | 0.06 |
| Sales Growth | 19.53% |
| Promoter Holding | 61.99% |
| 52-Week Range | ₹697.4 — ₹1,097.9 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹224.05 |
Windlas Biotech trades with a P/E ratio of 23.84, ROCE of 16.96%, ROE of 14.15%, profit growth of -3.72%, debt-to-equity of 0.06. The FairStock Score of 33/100 flags concerns across multiple fundamental dimensions that investors should examine carefully.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer